Sandy Dimiterchik, an advocate for patients diagnosed with schizophrenia, leads the panel in a discussion highlighting barriers that inhibit optimal patient care. John J. Miller, MD:Sandy, what do you ...

Panelists discuss how evidence-based, patient-tailored guideline adherence enhances long-term schizophrenia outcomes.

File photo: Dr. Jeanie Tse, chief medical officer at the Institute for Community Living, administers antipsychotic medication to a patient living with schizophrenia in her home, Wednesday, May 6, 2020 ...

Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety ...

Credit: Getty Images A literature review of nonpharmacologic treatments for patients with schizophrenia and comparison recommendations in the 2020 American Psychiatric Association Practice (APA) ...

Patients with schizophrenia are at increased risk of developing inflammatory bowel disease (IBD) compared with the general population, according to large study from Taiwan that provides more evidence ...

Using lab-grown brain tissue, researchers uncovered complex patterns of neural signaling that differ subtly between healthy ...

In the months after 24-year-old D.J. was diagnosed with schizophrenia, he searched online for answers to questions that felt urgent and existential. Does it get really bad over time? Will I be able to ...

Reviva Pharmaceuticals said the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine after a ...